IDWeek 2019 — BioFire CNS assay decreases use of lumbar punctures


  • Devona Williams, Pharm.D.
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Rapid identification of central nervous system (CNS) pathogens with BioFire Meningitis Enchephalitis PCR assay can help prevent repeat lumbar punctures (LP).

Why this matters

  • Patients admitted to a hospital with symptoms of meningitis or encephalitis are at risk for adverse clinical outcomes.
  • Faster diagnosis and confirmation of CNS organisms can prevent repeat LP and decrease unnecessary antimicrobial therapies.

Study design

  • Retrospective review initiated by clinical staff.
  • Cerebrospinal fluid (CSF) samples were obtained from the microbiology laboratory from patients who had been admitted with symptoms of meningitis or encephalitis.
  • Testing was performed on CSF specimens that had not been centrifuged via BioFire FilmArray Meningitis Encephalitis PCR assay.
  • Funding: None.

Key results

  • Pediatric and adult patients were included for analysis (27.1% and 72.8%).
  • Repeat LP required: 21.4%.
  • Median time to repeat LP: 4 days.
  • Median time to BioFire organism diagnosis: 26 hours.
  • Patients with negative BioFire were often prescribed antiviral and antibiotic therapy (47.8% and 97.8%).
  • BioFire identified a pathogen in 33.3% of patients with a discharge diagnosis of unknown etiology using conventional methods.

Limitations

  • Single-center review.
  • Results presented at a conference and not peer-reviewed.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit